Eli Lilly and Company

Agouron Pharmaceuticals, Inc.

Montana State University

Michael J Rodriguez

Siegfried Heinz Reich

John Howard Tatlock

Vincent J Kalish

Bruce Anthony Dressman

Timothy Alan Shepherd

Stephen W Kaldor

James E Fritz

John E Munroe

William Joseph Hornback

Mark J Zweifel

Marlys Hammond

James Andrew Jamison

Robin D Cooper

Nancy June Snyder

Gaiying Zhao

Sajan Joseph

Richard Craig Thompson

William Thomas McMillen

Bret E Huff

Stephen Charles Wilkie

Johnathan Alexander McLean

Michael A Staszak

Guillermo S Cortez

Thalia I Nicas

John T Quatroche

John Gordon Allen

William W Turner

Frantz Victor

Christopher Stanley Galka

Karin Briner

Maria Angeles Martinez-Grau

Deyi Zhang

Roger Ryan Rothhaar

Michael Wade Tidwell

Matthew Robert Reinhard

Venkatraghavan Vasudevan

Lisa M LaGrandeur

Gary Allan Strobel

Steven Armen Boyd

Jolie Anne Bastian

Louis Nickolaus Jungheim

James Robert Henry

Deqi Guo

Andrew Caerwyn Williams

Peter S Borromeo

Richard Duane Johnston

Ajay Singh

Almudena Rubio

Michael Philip Cohen

Michael Philip Mazanetz

David Anthony Barda

Jason Eric Lamar

Kelly Wayne Furness

Mohammad Sadegh Zia-Ebrahimi

Chong Si

Sarah Lynne Hellman

Santiago Carballares Martin

Sonia Maria Gutierrez Sanfeliciano

Pablo Garcia Losada

Wenceslao Lumeras Amador

Isabel Rojo

Tao Liu

Venkatraghaven Vasudevan

Matthew Patrick Baumgartner

Arundhati S Deo

Mario Barberis

Wai-Man Lee

Victoriano Molero Florez

Maria Lourdes Prieto Vallejo

Christopher Stephen Siedem

Yesenia Leonor Hipolito

The present invention provides compounds of the formula:

KRas inhibitors

Bendable hair rod with clasp

The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.

ERK inhibitors

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where:

[object Object]

Appliance carrier

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HTreceptor agonists for the treatment of 5-HTassociated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: 

Plants and crops subject to attack by fungal related diseases are protected or treated by the application ofcompositions which were originally isolated from

Pseudomycins useful against plant diseases

Method of making HIV protease inhibitors

Cyclic peptide antifungal agents

Compounds useful as intermediates in the preparation of HIV protease inhibitors. These compounds have the following general formula:

HIV protease inhibitors

The present invention relates to compounds of formula

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optionally other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

HIV protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of the HIV protease enzyme, causing the replication of the HIV virus to terminate. These compounds, as well as pharmaceutical compositions that contain these compounds and optically other anti-viral agents as active ingredients, are suitable for treating patients or hosts infected with the HIV virus, which is known to cause AIDS.

Pharmaceutical compositions containing HIV protease inhibitors and

Growing community of inventors

Indianapolis, IN, United States of America

Michael J Rodriguez